Infection and drug resistance · 2026
Two Case Reports of Drug-Resistant Tuberculous Pleurisy in Children: Thoracoscopic Pleural Biopsy and PCR-Based Drug-Resistance Testing.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Yunlian, Guo Qin, Li Yiyuan, Jiang Fangyong, He Ruoxi, Zhu Yu
Аннотация
BACKGROUND: Drug-resistant tuberculous pleurisy is difficult to diagnose in children because pleural fluid is paucibacillary, culture is slow and frequently negative, and Xpert detects only rifampicin resistance.
CASE PRESENTATION: We report two children in whom thoracoscopic pleural biopsy combined with PCR-high-resolution melting (HRM) drug-resistance testing identified drug-resistant tuberculosis. Case 1, an 8-year-old girl with tuberculous pleurisy, showed persistent pleural thickening and a new mass after two months of standard first-line therapy; pleural tissue PCR detected rpoB and inhA mutations, confirming multidrug-resistant tuberculosis (MDR-TB), and she responded to an all-oralbedaquiline- and delamanid-containing regimen. Case 2, a 9-year-old boy with loculated tuberculous pleurisy and negative cultures, had an rpoB mutation confirming rifampicin-monoresistant tuberculosis; he recovered with a rifampicin-sparing regimen and remained relapse-free at one year.
CONCLUSION: In pediatric tuberculous pleurisy, particularly when fluid-based testing is uninformative or first-line therapy fails, thoracoscopic pleural biopsy combined with molecular drug-resistance testing of tissue is decisive for detecting occult drug-resistant tuberculosis and enabling timely, individualized treatment.
CASE PRESENTATION: We report two children in whom thoracoscopic pleural biopsy combined with PCR-high-resolution melting (HRM) drug-resistance testing identified drug-resistant tuberculosis. Case 1, an 8-year-old girl with tuberculous pleurisy, showed persistent pleural thickening and a new mass after two months of standard first-line therapy; pleural tissue PCR detected rpoB and inhA mutations, confirming multidrug-resistant tuberculosis (MDR-TB), and she responded to an all-oralbedaquiline- and delamanid-containing regimen. Case 2, a 9-year-old boy with loculated tuberculous pleurisy and negative cultures, had an rpoB mutation confirming rifampicin-monoresistant tuberculosis; he recovered with a rifampicin-sparing regimen and remained relapse-free at one year.
CONCLUSION: In pediatric tuberculous pleurisy, particularly when fluid-based testing is uninformative or first-line therapy fails, thoracoscopic pleural biopsy combined with molecular drug-resistance testing of tissue is decisive for detecting occult drug-resistant tuberculosis and enabling timely, individualized treatment.